Pembrolizumab + Olaparib
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma, Ocular Melanoma
Trial Timeline
Oct 11, 2022 → Dec 1, 2027
NCT ID
NCT05524935About Pembrolizumab + Olaparib
Pembrolizumab + Olaparib is a phase 2 stage product being developed by Merck for Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05524935. Target conditions include Uveal Melanoma, Ocular Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05379972 | Phase 2 | Active |
| NCT05524935 | Phase 2 | Recruiting |
| NCT05156268 | Phase 2 | Active |
| NCT04666740 | Phase 2 | Active |
| NCT04483544 | Phase 2 | Terminated |
| NCT03025035 | Phase 2 | Completed |
Competing Products
20 competing products in Uveal Melanoma